Literature DB >> 15726369

Effects of docetaxel on antigen presentation-related functions of human monocyte-derived dendritic cells.

Hiroshi Nakashima1, Akira Tasaki, Makoto Kubo, Hideo Kuroki, Kotaro Matsumoto, Masao Tanaka, Masafumi Nakamura, Takashi Morisaki, Mitsuo Katano.   

Abstract

PURPOSE: Docetaxel (TXT) is a unique chemotherapeutic agent that has been approved for treating various types of malignancies. TXT stabilizes microtubule assembly in cells and causes various dysfunctions of microtubule-dependent cellular events. Patients with advanced malignancies are beginning to receive TXT in combination with immunotherapy; however, the influence of TXT at clinically achievable serum concentrations (less than 10(-6) M) on antigen presentation-related functions of human monocyte-derived dendritic cells (Mo-DCs) remains unclear.
METHODS: Immature Mo-DCs (imMo-DCs) were generated from peripheral blood monocytes with interleukin-4 and granulocyte-macrophage colony-stimulating factor in vitro. Mature Mo-DCs (mMo-DCs) were induced from imMo-DCs with tumor necrosis factor-alpha and prostaglandin E(2).
RESULTS: TXT at concentrations lower than 10(-7) M did not significantly affect cellular viability, phagocytosis, or expression of antigen presentation-related molecules of Mo-DCs. In contrast, TXT at concentrations lower than 10(-9) M significantly suppressed directional motility of imMo-DCs toward MIP-1alpha and of mMo-DCs toward MIP-3beta. However, TXT had no effect on either CCR1 expression by imMo-DCs or CCR7 expression by mMo-DCs. No gross changes in the microtubule skeleton were evident by immunofluorescence microscopy after treatment with TXT at less than 10(-8) M. However, reduced numbers of imMo-DCs with podosomes localized primarily in one cell region were observed.
CONCLUSIONS: The present results indicate that different concentrations of TXT influence antigen presentation-related functions differently. In particular, TXT at relatively low therapeutic doses disrupts chemotactic motility of Mo-DCs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726369     DOI: 10.1007/s00280-004-0918-7

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  5 in total

1.  Combined treatment with bevacizumab and standard chemotherapy restores abnormal immune parameters in advanced colorectal cancer patients.

Authors:  Nikolaos Tsavaris; Ioannis F Voutsas; Christos Kosmas; Angelos D Gritzapis; Constantin N Baxevanis
Journal:  Invest New Drugs       Date:  2010-09-07       Impact factor: 3.850

2.  Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations.

Authors:  Ramon Kaneno; Galina V Shurin; Irina L Tourkova; Michael R Shurin
Journal:  J Transl Med       Date:  2009-07-10       Impact factor: 5.531

3.  Differential effects of Paclitaxel on dendritic cell function.

Authors:  Justin John; Mohammed Ismail; Catherine Riley; Jonathan Askham; Richard Morgan; Alan Melcher; Hardev Pandha
Journal:  BMC Immunol       Date:  2010-03-19       Impact factor: 3.615

4.  Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism.

Authors:  Galina V Shurin; Irina L Tourkova; Ramon Kaneno; Michael R Shurin
Journal:  J Immunol       Date:  2009-06-17       Impact factor: 5.422

5.  Selective interaction of PEGylated polyglutamic acid nanocapsules with cancer cells in a 3D model of a metastatic lymph node.

Authors:  Marta Alonso-Nocelo; Raquel Abellan-Pose; Anxo Vidal; Miguel Abal; Noemi Csaba; Maria Jose Alonso; Rafael Lopez-Lopez; Maria de la Fuente
Journal:  J Nanobiotechnology       Date:  2016-06-23       Impact factor: 10.435

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.